Children with hypodiploid acute lymphoblastic leukemia fare better when minimal residual disease is used to guide treatment.
Research led by St. Jude Children's Research Hospital means more than 90 percent of the most common cases of childhood cancer can now be classified by subtype, an advance likely to fuel precision medicine.
Investigators studied the effects of the H3 K27M mutation, and revealed its impact on mutations that are known drivers of DIPGs.
Read about the newly identified subset of helper T 17 immune cells that suggest a novel approach for taming chronic inflammation.
Scientific discovery by St. Jude group could lead to new pathway for cancer treatment and understanding of ALS.
The 2018 annual meeting of the American Society of Hematology will include research from St. Jude that stretches from the laboratory to the clinic.
St. Jude scientists and clinicians highlighted at the annual American Society of Hematology in San Diego. Read the latest.
The Public Resource of Patient-derived and Expanded Leukemias (PROPEL) offers patient-derived xenograft samples free of charge for researchers worldwide.
A surprising mechanism that might explain how the Hippo signaling pathway promotes solid tumor growth.
Common genetic variations may help find female childhood cancer survivors at increased risk of breast cancer and who are candidates for stepped up screening.
Explore more research news
More Research News
Clinical Trials Alerts
Our e-newsletter for clinicians offers updates on St. Jude open clinical trials and research news.
Courageous patients. Resolute doctors. Caring staff. Inventive scientists. Their voices come alive in Promise magazine.
Follow Us on Social Media
Connect with @stjuderesearch to keep up with our latest science and medical news. More about St. Jude social media.
Browse all scientific publications by St. Jude investigators.